Collider in RCT Subgroup Analysis

s_doi:

If dexamethasone works by suppressing inflammation, and oxygen requirement reflects how far that inflammation has already progressed, then the greatest causal contribution of dexamethasone should be in patients not yet requiring oxygen, where the drug intercepts the inflammatory process earliest, before irreversible lung injury has occurred. Yet RECOVERY’s subgroup analysis shows no benefit in that group. This means the subgroup gate may have systematically misidentified where the biological process actually generates the treatment response.

There are biological and mathematical reasons not to draw this conclusion. COVID virus infection only uncommonly produces the hyper immune response which is potentially fatal so treating early could be dilutional and potentially harmful, I discussed the potential for corticosteroid induced harm when only a weak antiviral safety net is available in my discussion of the CAP trials.

s_doi:

conditioning on a mediator proxy may artificially partition what is actually a single continuous biological process into apparent subgroups that do not correspond to distinct natural disease states. In other words, a coherent biological process at the main gate can generate what amounts to a synthetic data generating process (SDGP) at the subgroup level, not through disease mixture as you describe, but through causal pathway mixture induced by the subgroup gate itself

I agree with you and this is a very important contribution because it was not part of my original framework relevant SDGP trials.

I will acknowledge that grade A may be over generous because it rests on a subset and biologic assumptions.

I like your pathway analysis but the question remains. How does one enrich for the biologic treatment target and at the same time mitigate the potential for generating a synthetic pathway partition?